Figure 3.

Proportion of participants with HIV-1 RNA <50 copies/mL by subgroup in the ITT-E population by FDA Snapshot algorithm at week 48. ^aIncludes American Indian or Alaska Native or individuals of multiple races. ^bThe study population was stratified by baseline third agent class (PI, INSTI, or NNRTI). ^cAdjusted difference for overall population (DTG/3TC − CAR) and 95% CIs are based on a stratified analysis (adjusting for baseline third agent class) using Cochran-Mantel-Haenszel weights (meeting noninferiority based on −12% margin); unadjusted difference for subgroups calculated by proportion on DTG/3TC − proportion on CAR. Abbreviations: CAR, current antiretroviral regimen; CI, confidence interval; DTG/3TC, dolutegravir/lamivudine; FDA, Food and Drug Administration; HIV-1, human immunodeficiency virus 1; INSTI, integrase strand transfer inhibitor; ITT-E, intention-to-treat–exposed; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.